Because IL-6 is a critical cytokine known to promote CCA progression by activating JAK2/STAT3 signaling, we investigated whether PA-CM inhibited IL-6-induced JAK2/STAT3 activation in CCA cells. The gene discussed is JAK2; the disease is cholangiocarcinoma.